Werewolf Therapeutics

Company snapshot

Many diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. Our first-in-class small molecules are developed to control T cell activation by modulating antigen presentation, altering how cells appear to the immune system so it can recognize and target them correctly. Our oncology treatment (GRWD5769) is delivering promising Phase 1/2 data in patients w

• 2 active pipeline program(s) linked via ClinicalTrials.gov.
• 10 US patent(s) indexed to this assignee profile.
• 2 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Werewolf Therapeutics. Not investment advice.

• Peer + 0 momentum

  Coherus Oncology

  TA overlap score 25

Recent activity

Latest pipeline, patent, and corporate events for Werewolf Therapeutics.

1. May 23, 2026 Clinical update

   WTX-330 — Phase 2

2. May 23, 2026 Clinical update

   WTX-124 — Phase 1

3. Apr 15, 2025 Patent grant

   Activatable interleukin 12 polypeptides and methods of use thereof

4. Sep 3, 2024 Patent grant

   Activatable cytokine polypeptides and methods of use thereof

5. Jul 16, 2024 Patent grant

   Activatable cytokine polypeptides and methods of use thereof

View all clinical trial activity →

• What is Werewolf Therapeutics?

  Greywolf Therapeutics is a pharma organization headquartered in Milton, GB. It trades on NYSE under ticker HOWL. Primary therapeutic focus areas include Metastatic Solid Tumor, Advanced or Metastatic Solid Tumors. NovaPharmaNews links 2 clinical program(s), 0 drug profile(s), and

• Is Werewolf Therapeutics publicly traded?

  Yes. Werewolf Therapeutics is listed with ticker HOWL on NYSE per SEC EDGAR records linked on this profile.

• What drugs does Werewolf Therapeutics develop or market?

  No drug profiles are currently linked to Werewolf Therapeutics. Pipeline programs may still list investigational assets.

• What are the latest developments for Werewolf Therapeutics?

  In the last 12 months our linked public records show 2 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Werewolf Therapeutics focus on?

  Werewolf Therapeutics focuses on Metastatic Solid Tumor, Advanced or Metastatic Solid Tumors based on our analysis of their pipeline programs and drug development activities.